Cargando…
Once-daily treatment of ADHD with guanfacine: patient implications
The standard of care for treating ADHD is to use a psychostimulant as the first line agent. Recent medical literature reports that approximately 70%–90% of patients with ADHD received some benefit from a stimulant medication. Even though psychostimulants have a high rate of efficacy, an estimated 30...
Autor principal: | Strange, Brandon C |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2526381/ https://www.ncbi.nlm.nih.gov/pubmed/18830439 |
Ejemplares similares
-
Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients
por: Antonini, Angelo, et al.
Publicado: (2011) -
Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?
por: Nachega, Jean B, et al.
Publicado: (2011) -
Efficacy and safety of once-daily single-inhaler triple therapy in patients with inadequately controlled asthma: the CAPTAIN trial
por: Ojanguren, Iñigo, et al.
Publicado: (2021) -
Once-monthly paliperidone injection for the treatment of schizophrenia
por: Bishara, Delia
Publicado: (2010) -
Atomoxetine: a novel treatment for child and adult ADHD
por: Ledbetter, Marcialee
Publicado: (2006)